Company Overview of NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a drug discovery company, identifies and develops transformational biologics for the treatment of diabetes, obesity, muscle wasting, and other cardio metabolic diseases. It focuses on mining the complex biological interactions within the neuroendocrine gastrointestinal (GI) environment to elucidate the roles of previously unidentified or unexplored hormones, receptors, and other metabolic factors that are involved in the systemic regulation of glucose homeostasis and that play causative roles in diseases. The company also develops novel therapeutics to modulate beta-cell regeneration for the treatment of Type 1 and Type 2 diabetes. In addition, its surgical mode...
630 Gateway Boulevard
South San Francisco, CA 94080-7014
Founded in 2007
Key Executives for NGM Biopharmaceuticals, Inc.
Chief Executive Officer and Director
Founder, Chief Scientific Officer and Director
Chief Medical Officer and Vice President
Vice President of Business Development
Compensation as of Fiscal Year 2014.
NGM Biopharmaceuticals, Inc. Key Developments
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
Feb 23 15
NGM Biopharmaceuticals, Inc. and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis (NASH). NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94 million and will purchase a 15% equity stake in NGM for $106 million at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250 million to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
NGM Biopharmaceuticals, Inc. - Special Call
Feb 23 15
To discuss about multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas with Merck
NGM Biopharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 09:00 AM
Jan 7 15
NGM Biopharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 09:00 AM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Jeff Jonker, President.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 23, 2015
October 9, 2014